title: Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia.
abstract: Clofarabine is a second-generation purine nucleoside analogue, which has shown promising activity in relapsed and refractory paediatric acute lymphoblastic leukaemia (ALL). This report summarizes the early United Kingdom experience of clofarabine for the treatment of paediatric ALL in 23 patients, outside of the context of a clinical trial. Our results demonstrated that clofarabine-based chemotherapy regimes were effective and well-tolerated in this heavily pre-treated group, with an overall response rate of 67% when used in combination regimes. Responses were seen in both B and T cell disease and in patients with adverse cytogenetics.
authors.affiliation: Department of Haematology, Birmingham Children's Hospital, Birmingham, UK. doconnor@doctors.org.uk
authors.forename: David
authors.initials: D
authors.lastname: O'Connor
authors.forename: Keith
authors.initials: K
authors.lastname: Sibson
authors.forename: Mark
authors.initials: M
authors.lastname: Caswell
authors.forename: Philip
authors.initials: P
authors.lastname: Connor
authors.forename: Michelle
authors.initials: M
authors.lastname: Cummins
authors.forename: Chris
authors.initials: C
authors.lastname: Mitchell
authors.forename: Jayashree
authors.initials: J
authors.lastname: Motwani
authors.forename: Mary
authors.initials: M
authors.lastname: Taj
authors.forename: Ajay
authors.initials: A
authors.lastname: Vora
authors.forename: Robert
authors.initials: R
authors.lastname: Wynn
authors.forename: Pamela R
authors.initials: PR
authors.lastname: Kearns
mesh_terms: D000227:Adenine Nucleotides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000293:Adolescent; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001087:Arabinonucleosides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D000077866:Clofarabine; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D000227:Adenine Nucleotides; D000970:Antineoplastic Agents; D001087:Arabinonucleosides; D000077866:Clofarabine